Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition

Core Insights - First Turn Management sold its entire stake of 313,733 shares in Arcellx for approximately $25.76 million, as disclosed in an SEC filing on February 13, 2026 [1][2] Company Overview - Arcellx is a clinical-stage biotechnology company focused on developing novel cell-based immunotherapies for cancer treatment, with a diversified pipeline targeting hematologic malignancies and solid tumors [5] - The company has a market capitalization of $3.96 billion, with a revenue of $35.90 million and a net income of -$217.90 million for the trailing twelve months (TTM) [4] Financial Performance - As of February 13, 2026, Arcellx shares were priced at $68.50, reflecting a 7.5% increase over the past year, although this performance lagged behind the S&P 500 by 4.3 percentage points [7] - The company's stock faced pressure due to competitive concerns, particularly related to CAR-T data from Kelonia Therapeutics [9] Investment Implications - The sale of Arcellx shares by First Turn Management suggests a consolidation of conviction in its portfolio, as the fund holds larger positions in other biotech companies [6] - The performance of Arcellx shares, while not catastrophic, indicates a lack of relative strength necessary for a concentrated, high-risk biotech strategy [7]